Suppressed protein halted melanoma metastasis

Share this content:

Inhibiting a specific protein eliminated metastasis of melanoma in laboratory experiments, a finding that could lead to targeted therapies to stop metastasis in not only melanoma but, potentially, a broad range of cancers.

In the study, Raf kinase inhibitor protein (RKIP) was found to bind with melanoma differentiation associated gene-9 (MDA-9), also known as syntenin, which functions as a positive regulator of melanoma progression and metastasis. Previous research demonstrated that interaction between MDA-9 and another protein, c-Src, led to increased metastasis.

The investigators learned that when RKIP binds to MDA-9, MDA-9 expression is inhibited, as they explained in Cancer Research (2012;72[23]:6217-6226). They also found that MDA-9 levels were higher than RKIP levels in malignant and metastatic melanoma cells, whereas RKIP levels were higher than MDA-9 levels in healthy melanocytes. Changes in levels of expression of these two proteins could potentially be used as a tool to track the development of melanoma or a patient's response to treatment.

Because earlier studies have shown that MDA-9 is elevated in a majority of cancers, the current findings could be applicable to a wide range of diseases.

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs